Novel views on new-onset diabetes after transplantation: development, prevention and treatment
Open accessThe DOI matches its Crossref record; 183 of the 187 references it cites were found in a registry or an index.
Abstract
New-onset diabetes after transplantation (NODAT) is associated with increased risk of allograft failure, cardiovascular disease and mortality, and therefore, jeopardizes the success of renal transplantation. Increased awareness of NODAT and the prediabetic states (impaired fasting glucose and impaired glucose tolerance, IGT) has fostered previous and present recommendations, based on the management of type 2 diabetes mellitus (T2DM). Unfortunately, the idea that NODAT merely resembles T2DM is potentially misleading, because the opportunity to initiate adequate anti-hyperglycaemic treatment early after transplantation might be given away for 'tailored' immunosuppression in patients who have developed NODAT or carry personal risk factors. Risk factor-independent mechanisms, however, seem to render postoperative hyperglycaemia with subsequent development of overt or 'full-blown' NODAT, the unavoidable consequence of the transplant and immunosuppressive process itself, at least in many cases. A proof of the concept that timely preventive intervention with exogenous insulin against post-transplant hyperglycaemia may decrease NODAT was recently provided by a small clinical trial, which is awaiting confirmation from a multicentre study. However, because early insulin therapy aimed at beta-cell protection seems to contrast the currently recommended, stepwise approach of 'watchful waiting' prior to pancreatic decompensation, we here aim at reviewing recent concepts regarding the development, prevention and treatment of NODAT, some of which seem to challenge the traditional view on T2DM and NODAT. In summary, we suggest a novel, risk factor-independent management approach to NODAT, which includes glycaemic monitoring and anti-hyperglycaemic treatment in virtually everybody after transplantation. This approach has widespread implications for future research and is intended to tackle NODAT and also ultimately cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The OGTT is considered the goldstandard test for the diagnosis of PTDM (1 year posttransplant) (138,139,148,149).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [139]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Hyperglycemia is very common during the early posttransplant period, with 90% of kidney allograft recipients exhibiting hyperglycemia in the fi rst few weeks following transplant (138,139,141,142).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [139]
The cited source says what the claim attributes to it.
In the citing paper
“Hyperglycemia is very common during the early posttransplant period, with 90% of kidney allograft recipients exhibiting hyperglycemia in the first few weeks following transplant (138,139,141,142).”
From 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025 (2025) · cites this paper as [139]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s062 · Cited by 13,988
Lee, I.-M., Shiroma, E. J., Lobelo, F., Puska, P., Blair, S. N., & Katzmarzyk, P. T. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61031-9 · Cited by 8,215
Wolfe, R. A., Ashby, V. B., Milford, E. L., Ojo, A. O., Ettenger, R. E., Agodoa, L. Y. C., Held, P. J., & Port, F. K. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912023412303 · Cited by 5,371
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Sugar-Sweetened Beverages and Risk of Metabolic Syndrome and Type 2 Diabetes
Malik, V. S., Popkin, B. M., Bray, G. A., Després, J.-P., Willett, W. C., & Hu, F. B. (2010) · Diabetes Care · doi:10.2337/dc10-1079 · Cited by 2,116
Weyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940 · cited 1×
“These distinctions imply different physiological interpretations, although it may not be trivial to make inferences about treatment for T2DM, as a consequence of further untangling this puzzling relationship [131].”
BackgroundU.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Sugar-Sweetened Beverages, Obesity, Type 2 Diabetes Mellitus, and Cardiovascular Disease Risk
Malik, V. S., Popkin, B. M., Bray, G. A., Després, J.-P., & Hu, F. B. (2010) · Circulation · doi:10.1161/circulationaha.109.876185 · Cited by 1,641
Immunosuppressive Drugs for Kidney Transplantation
Halloran, P. F. (2004) · New England Journal of Medicine · doi:10.1056/nejmra033540 · Cited by 1,555
Research works printed but not linked: 4
- 1984, American Journal of Physiology - Gastrointestinal and Liver Physiology, 247, E592
- 1992, American Journal of Physiology - Gastrointestinal and Liver Physiology, 263, E663
- Cerasi E. β-Cell dysfunction vs insulin resistance in type 2 diabetes: the eternal ‘chicken and egg’ question. Medicographia N° 106. 2011;33:35–41. [Google Scholar]
- Sharif A. Metformin safety post-transplantation—trials and tribulations. Am J Transplant. 2012;12:796. [Google Scholar]
Cited by
Items 101–121 of 121
NAUJAI IŠSIVYSTANTIS CUKRINIS DIABETAS PO INKSTŲ TRANSPLANTACIJOS
Alavočiūtė, U., Kantauskaitė, M., & Miglinas, M. (2015) · Medicinos teorija ir praktika · doi:10.15591/mtp.2015.107
Renal safety profile of di-peptidyl-peptidase inhibitors: a review of available literature
Dey, A., Unnikrishanan, A. G., Saxena, G., & Jain, R. (2017) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20170544
Jeddi, M., Aghasadeghi, F., Omrani, G. R., Malek‐Hosseini, S. A., & Lakarani, K. B. (2019) · Experimental and Clinical Transplantation · doi:10.6002/ect.2019.0158 · Cited by 1
Autosomal Dominant Tubulointerstitial Kidney Disease
Wolf, M. T. F., & Ariceta, G. (2021) · Springer eBooks · doi:10.1007/978-3-642-27843-3_120-1
Khan, M. T., Hamid, R. B., Hameed, B., & Lal, N. (2021) · Transplantation Proceedings · doi:10.1016/j.transproceed.2021.09.031
Complications of Pediatric Renal Transplantation
Dharnidharka, V. R., & Araya, C. E. (2015) · Springer eBooks · doi:10.1007/978-3-642-27843-3_67-1
Genetic Diseases Associated with Tubulointerstitial Nephritis
Wolf, M. T. F., Besse, W., Bleyer, A. J., & Dahl, N. K. (2022) · Springer eBooks · doi:10.1007/978-3-030-93438-5_11
DIABETES MELLITUS IN CATS AND DOGS: CLASSIFICATION AND ETIOLOGYS
(2022) · International Journal of Veterinary Science · doi:10.47278/book.ahp/2022.30
Bangash, W. G., Khokhar, S. Z., Maqsood, A., Rehman, H. U., Mahar, F. A., & Channa, A. A. (2021) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs2023173388
Management of new onset dysglycemia in transplant recipients
Sharif, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00045-1
Kurnikowski, A., Salvatori, B., Krebs, M., Budde, K., Eller, K., Pascual, J., Morettini, M., Göbl, C. S., Hecking, M., & Tura, A. (2024) · Biomedicines · doi:10.3390/biomedicines12020317
Kipp, A., Marti, H., Bábíčková, J., Nakken, S., Leh, S. M., Halden, T. A. S., Jenssen, T. G., Vikse, B. E., Åsberg, A., Spagnoli, G. C., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24037258
Çakmak, Ü., Merhametsiz, Ö., Akkaya, S., & Ay, N. (2025) · Anatolian Current Medical Journal · doi:10.38053/acmj.1796033
Kipp, A., Marti, H.-P., Bábíčková, J., Nakken, S., Leh, S. M., Halden, T. A. S., Jenssen, T., Vikse, B. E., Åsberg, A., Spagnoli, G., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24037255
Kipp, A., Marti, H.-P., Bábíčková, J., Nakken, S., Leh, S. M., Halden, T. A. S., Jenssen, T., Vikse, B. E., Åsberg, A., Spagnoli, G., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24037252
Kipp, A., Marti, H.-P., Bábíčková, J., Nakken, S., Leh, S. M., Halden, T. A. S., Jenssen, T., Vikse, B. E., Åsberg, A., Spagnoli, G., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24037261
Karaban, K., Żywiec, W., & Dorota, M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.4986
Crepaldi, M. C., Vedovato, M., Morieri, M. L., Basso, G., Stefanelli, L. F., Alessi, M., Fioretto, P., & Fadini, G. P. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01885-1
Kashiv, P., Pasari, A. S., Balwani, M., & Kute, V. (2026) · Cureus · doi:10.7759/cureus.112534
García-Sánchez, A., Ortiz‐Lazareno, P. C., Pazarín–Villaseñor, L., la Cruz, E. N. D.-D., Mora-Jiménez, A., Sierra, J. A., Cardona-Muñóz, E. G., Totsuka-Sutto, S. E., Gómez-Hermosillo, L. F., Casillas-Moreno, J., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198547
Metadata
- Authors
- Hecking, M., Werzowa, J., Haidinger, M., Horl, W. H., Pascual, J., Budde, K., Luan, F. L., Ojo, A., de Vries, A. P. J., Porrini, E., Pacini, G., Port, F. K., Sharif, A., Saemann, M. D., & European-New-Onset Diabetes After Transplantation Working Group
- Affiliations
- Medical University of Vienna (AT)
- Hospital Del Mar (ES)
- Charité – Universitätsmedizin Berlin (DE)
- University of Michigan (US)
- Universidad de La Laguna (ES)
- National Research Council (IT)
- Arbor Research Collaborative for Health (US)
- Queen Elizabeth Hospital Birmingham (GB)
- Corresponding author
- Hecking, M.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-01-17
- Volume
- 28
- Issue
- 3
- Pages
- 550-566
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- PMC
- PMC4375396
- OpenAlex
- W2164732183
- Cited by
- 120
- References
- 187
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 8 · 2023: 8 · 2022: 11 · 2021: 8 · 2020: 7 · 2019: 8 · 2018: 11 · 2017: 9 · 2016: 10 · 2015: 18 · 2014: 10 · 2013: 6
- FWCI
- 10.71
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nephrology Dialysis Transplantation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K24DK062234)
- Topics
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Keywords
- post-transplant diabetes mellitus, kidney transplantation, type 2 diabetes, immunosuppression, impaired glucose tolerance, impaired fasting glucose, exogenous insulin therapy, beta-cell protection, glycaemic monitoring, allograft failure, cardiovascular disease
- MeSH terms
- Diabetes Mellitus, Type 2, Humans, Risk Factors, Organ Transplantation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.